Floatz logo

Fludarabine

Castration-Resistant Prostate Cancer (CRPC)

Zhejiang UniversitySmall moleculePhase 1/2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Castration-Resistant Prostate Cancer (CRPC) cohort.

Asset / SponsorPhaseRating
177lu-betabart
Radiopharm Theranostics, Ltd
Phase 1/2CC
Dcc-3084
Deciphera Pharmaceuticals, LLC
Phase 1CC

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →